MARS® Bar Platform Brochure
Download the full MARS® Bar technical specifications as a PDF Brochure.
Webinar: Applying MARS® for Pre-Enrichment of Breast Cancer Disseminated Tumor Cells in Bone Marrow
Resources / Video Webinar: Applying MARS® for Pre-Enrichment of Breast Cancer Disseminated Tumor Cells in Bone Marrow I would like to access the webinar I already have the password More to Watch: Webinar: MARS® Platform Technology overview Gentle Nuclei Isolation from Tissue Samples Gentle Nuclei Isolation from Tissue Samples Webinar: Centrifuge-Free Matrix-Free Cell Isolation found […]
通过MARS®平台分选 CD3- CD56+ NK 细胞
NK细胞是目前肿瘤免疫治疗领域主要的创新目标。开发和改造基于NK细胞的癌症免疫疗法需要清洁且高效的小体积和大规模的细胞分离方法。创新产品MARS®Bar系统为CD56+/CD3-细胞分离提供了新一代大规模、磁分离技术，可以从单采血、全血或骨髓细胞制品中进行分离。
MARS® Bar Technical Specifications
Download the full MARS® Bar technical specifications as a PDF Brochure.
Webinar: MARS® Platform Technology overview
MARS® Bar among the Winners of The Scientist’s Top 10 Innovations of 2022
Santa Clara, California – We are thrilled to announce that MARS® Bar is among the Winners of The Scientist’s Top 10 Innovations of 2022! Each year The Scientist highlights the latest and greatest tools, technologies, and techniques to hit the life science landscape. This year’s crop of entries to The Scientist’s Top 10 Innovations contest […]
从激活血液中高效分离CD34+造血干细胞
近年来，多能造血干细胞（HSC）治疗因其一系列的具有希望的疗效已成为一种流行的技术。广泛的可能性使这种前沿治疗方法成 为现代医学的转折点。该技术面临的其中一个公认的挑战是为移植快速获得足够数量的高纯度的所需细胞类型。目前，耗时的样 品制备步骤和在此过程中大量细胞损失仍然是一个重大的挑战。MARS®平台通过一种简单的方法从激活的血液中分离CD34+细胞，而不需要RBC裂解和密度梯度离心。
CD3- CD56+ NK Cell Selection with MARS® Platform
NK cells are currently a major target of innovation in the field of cancer immunotherapy. Efforts aimed at developing and engineering NK cell-based cancer immunotherapy require clean and efficient methods of cell isolation at both small and large scales. The new MARS® Bar system enables a new generation of large scale, magnetic CD56+/CD3- cell isolation […]
Applied Cells Inc. and GenScript Enter Strategic Collaboration to Deliver Combined Solutions for Cell Therapy Development
Santa Clara, California, and Piscataway, New Jersey – November 18th, 2022. Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide. Under this collaboration, GenScript will develop and supply its proprietary research and cGMP grade CytoSinct™ reagents for use in developing […]
从全血中直接分离高纯度 CD138+浆细胞
骨髓浆细胞（BM）的细胞遗传学特异性特征是诊断和监测多发性骨髓瘤（MM）的一种常见的基因检测方法。多发性骨髓瘤患者的浆细 胞比例从1%到100%不等。尽管有些研究显示外周血中循环浆细胞（CPCs）比在骨髓中的风险低100倍以上，但由于其样本采集的侵入性 较低，它们的存在仍被认为是多发性骨髓瘤患者预后的一个重要标志。然而，耗时的样品制备步骤和在此过程中大量的细胞损失仍是一 个重大的挑战。MARS®平台通过一种简单的方法从外周血中分离CD138+浆细胞，而不需要RBC裂解和密度梯度离心。
